157 related articles for article (PubMed ID: 10561307)
41. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.
Isshi K; Sakuyama T; Gen T; Nakamura Y; Kuroda T; Katuyama T; Maekawa Y
Int J Clin Oncol; 2002 Dec; 7(6):335-42. PubMed ID: 12494248
[TBL] [Abstract][Full Text] [Related]
42. Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Ikeguchi M; Makino M; Kaibara N
Langenbecks Arch Surg; 2002 Oct; 387(5-6):240-5. PubMed ID: 12410361
[TBL] [Abstract][Full Text] [Related]
43. Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients.
Furuhata T; Kawakami M; Okita K; Kimura Y; Kihara C; Tsuruma T; Ohmura T; Yamaguchi K; Hata F; Katsuramaki T; Sasaki K; Hirata K
J Exp Clin Cancer Res; 2006 Mar; 25(1):79-82. PubMed ID: 16761622
[TBL] [Abstract][Full Text] [Related]
44. [Expression of dihydropyrimidine dehydrogenase in primary colorectal cancer and liver metastasis--a relationship between mRNA levels in cancer cells and protein levels in cancerous tissue and effect of 5-fluorouracil].
Ishibashi K; Sobajima J; Ishiguro T; Ohsawa T; Okada N; Miyazaki T; Yokoyama M; Inokuma S; Ishida H
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2232-5. PubMed ID: 20037380
[TBL] [Abstract][Full Text] [Related]
45. Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase.
Bi D; Anderson LW; Shapiro J; Shapiro A; Grem JL; Takimoto CH
J Chromatogr B Biomed Sci Appl; 2000 Feb; 738(2):249-58. PubMed ID: 10718643
[TBL] [Abstract][Full Text] [Related]
46. [Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity].
Yano A; Hashimoto K; Okuchi T; Mizoguchi H; Mutaguchi K; Nakamoto T; Usui T
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1877-83. PubMed ID: 11729480
[TBL] [Abstract][Full Text] [Related]
47. [Dihydropyrimidine dehydrogenase gene expression in patients with hepatic metastases from colorectal cancer].
Shirota Y; Ichikawa W; Yamada H; Uetake H; Nihei Z; Sugihara K
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1729-31. PubMed ID: 10560382
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
[TBL] [Abstract][Full Text] [Related]
49. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.
Ishikawa Y; Kubota T; Otani Y; Watanabe M; Teramoto T; Kumai K; Takechi T; Okabe H; Fukushima M; Kitajima M
Anticancer Res; 1999; 19(6C):5635-40. PubMed ID: 10697632
[TBL] [Abstract][Full Text] [Related]
50. Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and dpd-deficient dogs.
Inada M; Hirao Y; Koga T; Itose M; Kunizaki J; Shimizu T; Sato H
Drug Metab Dispos; 2005 Mar; 33(3):381-7. PubMed ID: 15616154
[TBL] [Abstract][Full Text] [Related]
51. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
Shepard DR; Mani S; Kastrissios H; Learned-Coughlin S; Smith D; Ertel P; Magnum S; Janisch L; Fleming GF; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2002 May; 49(5):398-402. PubMed ID: 11976834
[TBL] [Abstract][Full Text] [Related]
52. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice.
Ishikawa Y; Kubota T; Otani Y; Watanabe M; Teramoto T; Kumai K; Kitajima M; Takechi T; Okabe H; Fukushima M
Clin Cancer Res; 1999 Apr; 5(4):883-9. PubMed ID: 10213225
[TBL] [Abstract][Full Text] [Related]
53. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
54. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
55. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels.
Tanaka-Nozaki M; Onda M; Tanaka N; Kato S
Clin Cancer Res; 2001 Sep; 7(9):2783-7. PubMed ID: 11555593
[TBL] [Abstract][Full Text] [Related]
56. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.
Chazal M; Etienne MC; Renée N; Bourgeon A; Richelme H; Milano G
Clin Cancer Res; 1996 Mar; 2(3):507-10. PubMed ID: 9816197
[TBL] [Abstract][Full Text] [Related]
57. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
Rivera E; Sutton L; Colwell B; Graham M; Frye D; Somerville M; Conklin HS; McGuirt C; Levin J; Hortobagyi GN
J Clin Oncol; 2002 Feb; 20(4):987-93. PubMed ID: 11844821
[TBL] [Abstract][Full Text] [Related]
58. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
[TBL] [Abstract][Full Text] [Related]
59. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
Marsh JC; Catalano P; Huang J; Graham DL; Cornfeld MJ; O'Dwyer PJ; Benson AB
Clin Colorectal Cancer; 2002 May; 2(1):43-50. PubMed ID: 12453335
[TBL] [Abstract][Full Text] [Related]
60. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
